Director Makes Bold Move With Major MBX Biosciences Stock Purchase
JMP Securities Initiates MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $38
MBX Biosciences Initiated at Market Outperform by JMP Securities
MBX Biosciences Price Target Announced at $38.00/Share by JMP Securities
Express News | Guggenheim Reiterates Buy on MBX Biosciences, Maintains $44 Price Target
MBX Biosciences Analyst Ratings
Insider Purchase: Director at $MBX Buys 7,693 Shares
Press Release: MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Jefferies Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $35
MBX Biosciences Stock Jumps 5% on Clinical Trial Progress
MBX Biosciences | 10-K: FY2024 Annual Report
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025
MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027
MBX Biosciences | 8-K: MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Express News | Mbx Biosciences Inc - Phase 2 Trial of Mbx 1416 Expected to Begin in 2H 2025
MBX Biosciences 4Q Loss/Shr 47c >MBX
Press Release: MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Insiders' US$534.5k Investments In Red Following MBX Biosciences' US$62m Dip In Market Value
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide